HR Execs on the Move

M3 Biotechnology

www.m3bio.com

 
M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.m3bio.com
  • 4000 Mason Rd Suite 300 Box 352141
    Seattle, WA USA 98195
  • Phone: 206.221.8112

Executives

Name Title Contact Details
Leen Kawas
Chief Executive Officer Profile

Similar Companies

Endocyte Inc

Endocyte Inc is a West Lafayette, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ambys

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.

Optimer Pharmaceuticals

Optimer Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chart Industries

Chart is a recognized global brand for the design and manufacture of highly engineered cryogenic equipment used from the beginning to the end in the liquid gas supply chain.

Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company`s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic "off-the-shelf" cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.